WHO ICTRP trial
Is it safe to add cediranib to weekly paclitaxel chemotherapy in women with…
ISRCTN38690336 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN38690336 |
|---|---|
| Public title | Is it safe to add cediranib to weekly paclitaxel chemotherapy in women with ovarian cancer who are at risk of developing malignant bowel obstruction? |
| Scientific title | Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer |
| Primary sponsor | University of Manchester |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | United Kingdom;England |
| Conditions | Progressive, platinum-resistant or refractory, high-grade ovarian, fallopian tube or primary peritoneal cancer with high risk of bowel obstruction. Cancer Progressive, platinum-resistant or refractory, high-grade ovarian, fallopian tube or… |
| Interventions | This is a single arm trial where participants with recurrent platinum-resistant ovarian cancer and clinical and/or radiological features indicating an increased risk of developing subacute bowel obstruction. after registration participants… |
| Registration date | Jun 10, 2017 |
| Target size | 30 |
| Secondary IDs | 2016-004618-93;CEBOC01 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: